Research Topics
Genomes and GenesSpecies | Carsten GruendkerSummaryCountry: Germany Publications
| Collaborators
|
Detail Information
Publications
In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiolRobert Michael Hermann
Department of Radiotherapy and Radiooncology, University Hospital Goettingen, Robert Koch Str, 40, 37075, Goettingen, Germany
Radiat Oncol 3:19. 2008..As the majority of prostate cancers (PC) express estrogen receptors, we evaluated the combination of radiation and estrogenic stimulation (estrogen and genistein) on the radiosensitivity of PC cells in vitro...
Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancersCarsten Gründker
Department of Gynecology and Obstetrics, Robert Koch Street 40, D 37099 Göttingen, Germany
Mol Cancer Ther 4:225-31. 2005....- Role of gonadotropin-releasing hormone (GnRH) in ovarian cancerCarsten Gründker
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Street 40, D 37075 Gottingen, Germany
Reprod Biol Endocrinol 1:65. 2003..These data suggest that in ovarian cancer cells the antiproliferative effects of GnRH-I antagonist Cetrorelix and GnRH-II are not mediated through the GnRH-I receptor... 
Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancersCarsten Gründker
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Street 40, Gottingen 37075, Germany
Oncol Rep 26:629-35. 2011..The cytotoxic LHRH agonist AEZS-108 (AN-152) seems to be a suitable drug for treatment of LHRH receptor-positive human pancreatic cancers with little toxicity...- Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivoCarsten Gründker
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Street 40, 37075 Gottingen, Germany
Breast Cancer Res 12:R49. 2010..In addition, we ascertained whether knockdown of GnRH-I receptor expression affects GnRH-II antagonist-induced apoptosis and apoptotic signaling... - GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein BaxStefanie Fister
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Cancer Res 69:6473-81. 2009.... - Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cellsCarsten Gründker
Department of Gynecology and Obstetrics, Georg August University, D 37099 Göttingen, Germany
Eur J Endocrinol 151:619-28. 2004..In this study, we demonstrate that the GnRH agonist triptorelin inhibits estradiol (E2)-induced cancer cell proliferation... - Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cellsMartin Block
Department of Gynaecology and Obstetrics, Georg August University, Gottingen, Germany
Anticancer Res 30:2025-31. 2010..The aim of our study was to investigate single-agent and dual-agent therapeutic strategies in estrogen receptor-positive human EC cells... - Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cellsStefanie Fister
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Gynecol Endocrinol 24:24-9. 2008..After knock-down of GnRH receptor expression doxorubicin-induced apoptosis was decreased, indicating that GnRH agonists do not suppress chemotherapeutic drug-induced apoptosis in T-47-D breast cancer cells... - Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expressionAntje Schubert
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Gynecol Endocrinol 24:331-8. 2008..Since the osteolytic activity depends on the receptor activator of nuclear factor-kappaB (NFkappaB) ligand (RANKL)/osteoprotegerin (OPG) ratio, we analyzed RANKL and OPG expression in different breast-cancer cell lines... - Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivoStefanie Fister
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Street 40, D 37075 Gottingen, Germany
Cancer Res 67:1750-6. 2007..Thus, GnRH-II antagonists seem to be suitable drugs for an efficacious and less toxic endocrine therapy for endometrial and ovarian cancers... - Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152Gunter Emons
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Neuroendocrinology 90:15-8. 2009..A phase II study was started in January 2008... - Targeted chemotherapy for triple-negative breast cancers via LHRH receptorCrispin Föst
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Oncol Rep 25:1481-7. 2011..The cytotoxic LHRH agonist AEZS-108 (AN-152) seems to be a suitable drug for an efficacious therapy for triple-negative breast cancers with little toxicity... - Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cellsAndreas R Günthert
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Street 40, D 37075 Gottingen, Germany
Biochem Biophys Res Commun 294:11-5. 2002.... - GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organsNicola Eicke
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Street 40, D 37075 Gottingen, Germany
Eur J Endocrinol 153:605-12. 2005..Western blot analysis of the same gel using rabbit anti-human GnRH-II receptor antiserum identified this band as GnRH-II receptor-like antigen... - Analyzes of three common thrombophilic gene mutations in German women with recurrent abortionsHans Ulrich Pauer
Department of Gynecology and Obstetrics, University of Goettingen, Goettingen, Germany
Acta Obstet Gynecol Scand 82:942-7. 2003..Several etiological factors have been proposed as a cause for recurrent fetal abortions. Changes in blood coagulation during pregnancy may play an important role in the occurrence of recurrent abortions (RA)... - Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifenAndreas R Günthert
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Street 40, D 37075 Gottingen, Germany
Eur J Endocrinol 153:613-25. 2005..Through this mechanism, they probably reverse acquired resistance to 4OH-tamoxifen mediated through overexpression or activation of receptors of the c-erbB family... - Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptorCarsten Gründker
Department of Gynecology and Obstetrics, Georg August University, D 37070 Gottingen, Germany
Eur J Endocrinol 151:141-9. 2004..We were also able to show that the proliferation of human endometrial and ovarian cancer cells was dose- and time-dependently reduced by GnRH-II to a greater extent than by GnRH-I agonists... - Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fieldsRainer Girgert
Department of Gynecology and Obstetrics, University of Gottingen, Gottingen, Germany
Bioelectromagnetics 31:237-45. 2010..These results convincingly prove the negative effect of EMF on the antiestrogenic effect of melatonin in breast cancer cells... - Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: Evidence for a dose-window effectTeresa Olbrich
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Gynecol Oncol 119:571-8. 2010..In this study we have analyzed whether Kp-10 treatment affects bone-directed migration of GPR54-positive breast cancer cells... - Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cellsAndreas R Günthert
Department of Gynecology and Obstetrics, Georg August University, D 37075 Gottingen, Germany
Anticancer Res 24:1727-32. 2004..LHRH analogs protect human endometrial and ovarian cancer cells from DNA-replication-dependent cytotoxic agent and UV-light-induced apoptosis, but not from CD95-mediated apoptosis... - Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cellsRainer Girgert
Department of Gynecology and Obstetrics, University of Gottingen, Gottingen, Germany
Bioelectromagnetics 29:169-76. 2008..Electromagnetic fields may contribute to the induction of tamoxifen resistance in vivo... - Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferationCarsten Gründker
Department of Gynecology and Obstetrics, Georg August University, D 37070 Gottingen, Germany
J Clin Endocrinol Metab 87:1427-30. 2002..001). In the GnRH-II receptor positive but GnRH-I receptor negative ovarian cancer cell line SK-OV-3 native GnRH-II but not GnRH-I agonist Triptorelin had antiproliferative effects... - Hormonal heterogeneity of endometrial cancerCarsten Gründker
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Adv Exp Med Biol 630:166-88. 2008..This chapter reviews the current knowledge of the molecular mechanisms commonly associated with development of type I and type II endometrial cancer... - Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) systemAndreas R Günthert
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Strasse 40, D 37075 Gottingen, Germany
Am J Obstet Gynecol 191:1164-72. 2004..The surface expression of multidrug resistance-1 (MDR-1) gene product P-glycoprotein (Pgp) was measured by flow cytometry... - Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) systemAndreas R Günthert
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Breast Cancer Res Treat 87:255-64. 2004..These receptors can be used for targeted chemotherapy with agents like AN-152, in which doxorubicin is linked to analog [D-Lys6]LHRH. We compared the effects of AN-152 and doxorubicin in human breast cancer cells... - Funneling before and after anti-incontinence surgery--a prognostic indicator? Part 2: tension-free vaginal tapeLena Harms
Department of Gynecology and Obstetrics, Georg August University Goettingen, Goettingen, Germany
Int Urogynecol J Pelvic Floor Dysfunct 18:289-94. 2007..The TVT procedure significantly reduces bladder neck funneling. Both preoperative and persistent postoperative funneling are associated with an increased probability of therapeutic failure or recurrence... - Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblastsVolker Viereck
Department of Obstetrics and Gynecology, Georg August University of Goettingen, Goettingen, D 37075, Germany
Biochem Biophys Res Commun 291:680-6. 2002..Since, OPG production increases with osteoblastic cell maturation, enhancement of OPG by bisphosphonates could be related to their stimulatory effects on osteoblastic differentiation... - Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblastsVolker Viereck
Department of Obstetrics and Gynecology, Georg August University of Goettingen, Goettingen, Germany D 37075
J Clin Endocrinol Metab 88:4206-13. 2003..Because OPG production increases with osteoblastic maturation, enhancement of OPG production by raloxifene could be related to its stimulatory effects on osteoblastic differentiation... - Exposure of mcf-7 breast cancer cells to electromagnetic fields up-regulates the plasminogen activator systemRainer Girgert
Department of Obstetrics and Gynecology, University of Gottingen, Germany
Int J Gynecol Cancer 19:334-8. 2009..The use of our newly established exposure system for EMFs may allow us to study the signaling processes involved in the induction of a metastatic phenotype of breast cancer cells... - Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumorsGunter Emons
University Clinic Göttingen, Gottingen, Germany
Gynecol Oncol 119:457-61. 2010..The objectives of this first study in humans with AESZ-108 were to determine the maximum tolerated dose and to characterize the dose-limiting toxicity, pharmacokinetics, preliminary efficacy, and hormonal effects... - Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblastsVolker Viereck
Department of Obstetrics and Gynecology, Georg August University of Goettingen, Germany
J Cell Biochem 84:725-35. 2002..Thus, dietary sources of phytoestrogens may help to prevent bone resorption and bone loss by enhanced osteoblastic production of OPG... - Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitorCornelia E Wolf
Department of Transfusion Medicine, University of Gottingen, Gottingen, Germany
Pathophysiol Haemost Thromb 33:134-7. 2003..9/49 women with RPL showed coagulation disorders with heterozygous FV Leiden mutation (5), FXII (1), protein C (1) or protein S (2) deficiency. However, due to the small number of patients studied, no definite conclusion can be drawn... - Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblastsVolker Viereck
Department of Obstetrics and Gynecology, Georg August University of Gottingen, Gottingen, Germany
J Bone Miner Res 20:2036-43. 2005..The iCR effect, abrogated by the pure estrogen receptor antagonist ICI 182,780, also enhanced ALP activity (4-fold) and osteocalcin expression (3-fold), possibly contributing to the skeletal effects of black cohosh... - Mesengenic progenitor cells derived from human placentaGerald G Wulf
Department of Hematology and Oncology, Georg August University Goettingen, 37075 Goettingen, Germany
Tissue Eng 10:1136-47. 2004..In conclusion, we propose human term placenta as an easily accessible, ample source of multipotent mesengenic progenitor cells... - GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cellsNicola Eicke
Department of Gynecology and Obstetrics, Georg-August University, , Germany
Int J Oncol 29:1223-9. 2006..These data indicate, that the effects of GnRH-II are not due to a cross-reaction with the GnRH-I receptor. In conclusion these data suggest that the signaling of GnRH-II agonist [D-Lys6]GnRH-II is comparable to that of GnRH-I analogs... - GnRH analogs reduce invasiveness of human breast cancer cellsJulia von Alten
Department of Gynecology and Obstetrics, Georg-August-University, Robert-Koch-Street 40, , Germany
Breast Cancer Res Treat 100:13-21. 2006..Disruption of this interaction will allow us to design mechanism-based effective and specific therapeutic interventions for bone metastases... - Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivoAntje Schubert
Department of Gynecology and Obstetrics, Georg August University, Robert Koch Street 40, 37075 Gottingen, Germany
Breast Cancer Res Treat 130:783-90. 2011..Side effects were not detectable. In conclusion, GnRH analogs seem to be suitable drugs for an efficacious therapy for triple-negative, GnRH receptor-positive human breast cancers to prevent metastasis formation... - Factor XII deficiency is strongly associated with primary recurrent abortionsHans Ulrich Pauer
Department of Gynecology and Obstetrics, University Hospital of Goettingen, Goettingen, Germany
Fertil Steril 80:590-4. 2003..To evaluate factor XII deficiency in women with primary and secondary recurrent abortion... - Biology of the gonadotropin-releasing hormone system in gynecological cancersCarsten Gründker
Department of Gynecology and Obstetrics, Georg August University of Gottingen, Robert Koch Strasse 40, D 37070 Gottingen, Germany
Eur J Endocrinol 146:1-14. 2002..Furthermore, GnRH induces activation of the c-Jun N-terminal kinase/activator protein-1 (AP-1) pathway independent of the known AP-1 activators, protein kinase or mitogen activated protein kinase... - Sertoli-Leydig cell tumour in a 13-year-old girlBettina Bottcher
Department of Gynecology and Obstetrics, Georg August University Gottingen, Robert Koch Strasse, 37077 Gottingen, Germany
Gynecol Endocrinol 27:107-9. 2011..We describe the case of a Sertoli-Leydig cell tumour in a 13-year-old girl who presented with symptoms of hyperandrogenism. We give an overview over current literature and discuss options of therapy of rare Sertoli-Leydig cell tumours... - Atorvastatin stimulates the production of osteoprotegerin by human osteoblastsVolker Viereck
Department of Obstetrics and Gynecology, Georg August University, Goettingen, Germany
J Cell Biochem 96:1244-53. 2005..In summary, our data suggest that atorvastatin enhances osteoblastic differentiation and production of OPG. This may contribute to the bone-sparing effects of statins... - Urethral hypermobility after anti-incontinence surgery - a prognostic indicator?Volker Viereck
Department of Gynecology and Obstetrics, Georg August University Goettingen, Goettingen, Germany
Int Urogynecol J Pelvic Floor Dysfunct 17:586-92. 2006..Patients in whom hypermobility of the bladder neck diagnosed before surgery persists after colposuspension have a higher risk of recurrence and are more likely to develop postoperative complications than those without this hypermobility... - Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretionBoriana G Jahns
Department of Gynecology and Obstetrics, Georg August University, Gottingen, Germany
Am J Obstet Gynecol 199:e5-6. 2008..Recent experimental data implicate a causal role of prolactin. We report a patient with PPCM who responded well to treatment with Bromocriptine in addition to standard therapy of heart failure...